Carcinoma, Pancreatic Ductal

• 

  Subject Areas on Research

  • A Gastric Glycoform of MUC5AC Is a Biomarker of Mucinous Cysts of the Pancreas. 
  • A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients. 
  • A Quantitative Global Proteomics Approach Identifies Candidate Urinary Biomarkers That Correlate With Intraductal Papillary Mucinous Neoplasm Dysplasia. 
  • A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. 
  • A niche role for cancer exosomes in metastasis. 
  • A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. 
  • ACR Appropriateness Criteria® Staging of Pancreatic Ductal Adenocarcinoma. 
  • ASO Author Reflections: Progression after Resection of Noninvasive or Microinvasive Intraductal Papillary Mucinous Neoplasms. 
  • Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: an analysis of the surveillance, epidemiology, and end results registry. 
  • Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. 
  • Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence? 
  • CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. 
  • CT Radiomic Features of Superior Mesenteric Artery Involvement in Pancreatic Ductal Adenocarcinoma: A Pilot Study. 
  • CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. 
  • Cilia loss sensitizes cells to transformation by activating the mevalonate pathway. 
  • Clinical criteria for integrated molecular pathology in intraductal papillary mucinous neoplasm: less is more. 
  • Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. 
  • Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. 
  • Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. 
  • Current Controversy of Radiographic Surveillance of Patients With Branch-duct IPMN and Pancreatic Cysts: Commentary on: Ductal Carcinoma Arising in a Largely Unchanged Presumed Branch Duct IPMN After 10 Years of Surveillance. 
  • Cyst Fluid Analysis in Pancreatic Intraductal Papillary Mucinous Neoplasms. 
  • Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. 
  • DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. 
  • DNA profile components predict malignant outcomes in select cases of intraductal papillary mucinous neoplasm with negative cytology. 
  • Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. 
  • Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium. 
  • Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells. 
  • Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. 
  • Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. 
  • Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma. 
  • Differential Cell Susceptibilities to KrasG12D in the Setting of Obstructive Chronic Pancreatitis. 
  • Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. 
  • Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients. 
  • Dying tumor cells stimulate proliferation of living tumor cells via caspase-dependent protein kinase Cδ activation in pancreatic ductal adenocarcinoma. 
  • Dysplasia at the surgical margin is associated with recurrence after resection of non-invasive intraductal papillary mucinous neoplasms. 
  • Early Recurrence and Omission of Adjuvant Therapy after Pancreaticoduodenectomy Argue against a Surgery-First Approach. 
  • Early onset pancreatic malignancies: Clinical characteristics and survival associations. 
  • Effects of base excision repair gene polymorphisms on pancreatic cancer survival. 
  • Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. 
  • Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. 
  • Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancreatic cancer. 
  • FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. 
  • Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression. 
  • Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. 
  • Fibrogenesis in pancreatic cancer is a dynamic process regulated by macrophage-stellate cell interaction. 
  • GFRα1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling. 
  • GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma. 
  • GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs". 
  • Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. 
  • Hepatic arterial nodal metastases in pancreatic cancer: is this the node of importance? 
  • High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma. 
  • Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. 
  • ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer. 
  • Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma. 
  • Imaging comparison of tubular and colloid pancreatic adenocarcinoma arising from intraductal papillary mucinous neoplasm on multidetector CT. 
  • In vivo and in vitro propagation of intraductal papillary mucinous neoplasms. 
  • Incidentally discovered pancreatic intraepithelial neoplasia: what is its clinical significance? 
  • Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. 
  • Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. 
  • Interobserver agreement for detection of malignant features of intraductal papillary mucinous neoplasms of the pancreas on MDCT. 
  • Intraductal Oncocytic Papillary Neoplasms: Clinical-Pathologic Characterization of 24 Cases, With An Emphasis on Associated Invasive Carcinomas. 
  • Intraductal Papillary Mucinous Neoplasm of the Pancreas in Young Patients: Tumor Biology, Clinical Features, and Survival Outcomes. 
  • Intraductal Papillary Mucinous Neoplasms and the Risk of Diabetes Mellitus in Patients Undergoing Resection Versus Observation. 
  • Intraductal Tubulopapillary Neoplasm of the Pancreas: A Clinicopathologic and Immunohistochemical Analysis of 33 Cases. 
  • Intraductal papillary mucinous neoplasm. 
  • Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. 
  • Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? 
  • Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. 
  • Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. 
  • KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. 
  • Liberal resection for (presumed) Sendai negative branch-duct intraductal papillary mucinous neoplasms--also not harmless. 
  • Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. 
  • Loss of HNF6 expression correlates with human pancreatic cancer progression. 
  • Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. 
  • Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. 
  • Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation. 
  • Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. 
  • Measurement of Reactive Oxygen Species by Fluorescent Probes in Pancreatic Cancer Cells. 
  • Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 
  • MiR-135 suppresses glycolysis and promotes pancreatic cancer cell adaptation to metabolic stress by targeting phosphofructokinase-1. 
  • Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. 
  • Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. 
  • Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting. 
  • Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. 
  • Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2. 
  • Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma. 
  • Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. 
  • PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. 
  • PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. 
  • Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia. 
  • Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. 
  • Pancreatic cyst fluid concentration of high-mobility group A2 protein acts as a differential biomarker of dysplasia in intraductal papillary mucinous neoplasm. 
  • Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm. 
  • Pancreatic ductal adenocarcinoma with autoimmune pancreatitis-like histologic and immunohistochemical features. 
  • Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma. 
  • Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. 
  • Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. 
  • Peak density of immature nerve cells occurs with high-grade dysplasia in intraductal papillary mucinous neoplasms of the pancreas. 
  • Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. 
  • Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. 
  • Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. 
  • Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. 
  • Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. 
  • Predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: development of a preoperative nomogram. 
  • Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients. 
  • Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. 
  • Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. 
  • Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. 
  • Quantitative and Qualitative Comparison of Single-Source Dual-Energy Computed Tomography and 120-kVp Computed Tomography for the Assessment of Pancreatic Ductal Adenocarcinoma. 
  • Radiomic feature reproducibility in contrast-enhanced CT of the pancreas is affected by variabilities in scan parameters and manual segmentation. 
  • Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. 
  • Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. 
  • Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component): A Multi-institutional Analysis. 
  • Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. 
  • Roux-en-Y reconstruction after pancreaticoduodenectomy. 
  • SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms. 
  • Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. 
  • Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis. 
  • Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. 
  • Serum biomarker panels for the detection of pancreatic cancer. 
  • Should all branch-duct intraductal papillary mucinous neoplasms be resected? 
  • Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. 
  • Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. 
  • Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. 
  • Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. 
  • Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis. 
  • Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. 
  • TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. 
  • TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions. 
  • Targeting cell surface GRP78 enhances pancreatic cancer radiosensitivity through YAP/TAZ protein signaling. 
  • Targeting eNOS in pancreatic cancer. 
  • The Dilemma of the Dilated Main Pancreatic Duct in the Distal Pancreatic Remnant After Proximal Pancreatectomy for IPMN. 
  • The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. 
  • The Oncogenesis in Patients With Pancreatic Intraductal Papillary Mucinous Neoplasms: Taking the Thread From the Beginning. 
  • The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. 
  • The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma. 
  • The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. 
  • The efficacy and safety of the open approach irreversible electroporation in the treatment of pancreatic cancer: A systematic review. 
  • The management of intraductal papillary mucinous neoplasms of the pancreas. 
  • The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study. 
  • The outcome of resected cystic pancreatic endocrine neoplasms: a case-matched analysis. 
  • The subcellular localization of syntaxin 17 varies among different cell types and is altered in some malignant cells. 
  • Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. 
  • Transport properties of pancreatic cancer describe gemcitabine delivery and response. 
  • Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. 
  • Tumor-associated Neutrophils and Malignant Progression in Intraductal Papillary Mucinous Neoplasms: An Opportunity for Identification of High-risk Disease. 
  • Uncinate duct dilation in intraductal papillary mucinous neoplasms of the pancreas: a radiographic finding with potentially increased malignant potential. 
  • Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas. 
  • Widespread Repression of Gene Expression in Cancer by a Wnt/β-Catenin/MAPK Pathway. 
  • p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis.